ÖZET
Amaç:
Bu çalışmada amacımız, polikistik over sendromu tanısı olan ve olmayan hastalarda osteoprotegerin (OPG) düzeylerinin karşılaştırılması ve OPG düzeylerinin kardiyovasküler risk faktörleri ile ilişkisinin araştırılmasıdır.
Yöntemler:
Çalışmaya, aynı yaş ve vücut kitle indeksine sahip 49’u polikistik over sendromu ve 31’i kontrol grubunda olmak üzere toplam 80 hasta alındı. Hastalardan alınan kan örneklerinde, hormonal ve metabolik parametreler ile OPG düzeyleri değerlendirildi. Ultrasonografi ile her hastanın karotis arteri intima media kalınlığı ölçüldü.
Bulgular:
Biyokimyasal testler incelendiğinde, düşük dansiteli lipoprotein ve kolesterol düzeyleri ile homeostasis model assessment insulin indeks düzeyleri polikistik over grubunda daha yüksek bulundu (p=0,002, p=0,037, p=0,028). OPG düzeyi, polikistik over grubunda 4,29 pmol/L, kontrol grubunda ise 4,07 pmol/L saptandı. Her iki grupta karotis intima media kalınlığı 0,57 mm olarak ölçüldü.
Sonuç:
Çalışmada polikistik over grubu ile kontrol grubu arasında OPG düzeyleri ve karotis intima- media kalınlıkları açısından fark bulunmadı. Ayrıca OPG düzeyleri ile kardiyovasküler risk faktörleri arasında da bir bağlantı saptanmadı.
Anahtar Kelimeler:
Osteoprotegerin, polikistik over sendromu, ateroskleroz
Kaynaklar
1
Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004;89:2745-9.
2
Diamanti-Kandarakis E, Dunaif A.Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocrine Reviews 2012;33:981-1030.
3
Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Human Reproduction Update 2010;16:347-63.
4
Randeva HS, Tan BK, Weickert MO, et al. Cardiometabolic aspects of the polycystic ovary syndrome. Endocrine Reviews 2012;33:812-41.
5
Escobar-Morreale HF, Luque- Ramírez M, González F. Circulating inflammatory markers in polycystic ovary syndrome:a systematic review and metaanalysis. Fertility and Sterility 2011;95:1048-58.
6
Mozaffarian D, Benjamin EJ, Go AS, et al. Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation 2016;133:e38-60.
7
Rochette L, Meloux A, Rigal E, Zeller M, Cottin Y, Vergely C. The Role of Osteoprotegerin and Its Ligands in Vascular Function.Int J Mol Sci 2019;6;20:705.
8
Kiechl S, Werner P, Knoflach M, Furtner M, Willeit J, Schett G. The osteoprotegerin/RANK/ RANKL system: a bone key to vascular disease. Expert Rev Cardiovasc Ther 2006;4:801-11.
9
Schoppet M, Kavurma M, Hofbauer LC, Shanahan CM. Crystallizing nanoparticles derived fromvascular smooth muscle cells contain the calcification inhibitor osteoprotegerin.Biochemical and Biophysical Research Communications 2011;407:103-7.
10
Lawrie A, Waterman E, Southwood M, et al. Evidence of a role for osteoprotegerin in the pathogenesis of pulmonary arterial hypertension. American Journal of Pathology 2008;172:256-65.
11
Zannettino ACW, Holding CA, Diamond P, et al. Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with vonWillebrand factor. Journal of Cellular Physiology 2005;204:714-23.
12
Venuraju SM, Yerramasu A, Corder R, Lahiri A. Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity. Journal of theAmerican College of Cardiology 2010;55:2049-61.
13
Mangan SH, Van Campenhout A, Rush C, Golledge J. Osteoprotegerin upregulates endothelial cell adhesion molecule response to tumor necrosis factor-alpha associated with induction of angiopoietin-2. Cardiovasc Res 2007;76:494-505.
14
Candido R, Toffoli B, Corallini F, et al. Human full-length osteoprotegerin induces the proliferation of rodent vascular smooth muscle cells both in vitro and in vivo. J Vasc Res 2010;47:252-61.
15
Shin JY, Shin YG, Chung CH. Elevated serum osteoprotegerin levels are associated with vascular endothelial dysfunction in type 2 diabetes. Diabetes Care 2006;29:1664-6.
16
Xiang GD, Sun HL, Zhao LS. Changes of osteoprotegerin before and after insulin therapy in type 1 diabetic patients.Diabetes Research and Clinical Practice 2007;76:199-206.
17
Zagura M, Serg M, Kampus P, et al. Association of osteoprotegerin with aortic stiffness in patients with symptomatic peripheral artery disease and in healthy subjects. American Journal of Hypertension 2010;23:586-91.
18
Barbu CG, Arsene AL, Florea S, et al. Cardiovascular risk assessment in osteoporotic patients using osteoprotegerin as a reliable predictive biochemical marker. Mol Med Rep 2017;16:6059-67.
19
Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41-7.
20
Lieb W, Gona P, Larson MG, et al. Biomarkers of the osteoprotegerin pathway: clinical correlates, subclinical disease, incident CVD and mortality. Arterioscler Thromb Vasc Biol 2010;30:1849-54.
21
Jono S, Ikari Y, Shioi A, et al. Serum osteoprotegerin levels are associated with presence and severity of coronary artery disease. Circulation 2002;106:1192-4.
22
Sandberg WJ, Yndestad A, Oie E, et al. Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization. Arterioscler Thromb Vasc Biol 2006;26:857-63.
23
Semb AG, Ueland T, Aukrust P, et al. Osteoprotegerin and soluble receptor activator of nuclear factor-kappaB ligand and risk for coronary events: a nested case-control approach in the prospective EPIC-Norfolk population study 1993-2003. Arterioscler Thromb Vasc Biol 2009;29:975-80.
24
Abali R, Tasdemir N, Alpsoy S, et al. No relationship between osteoprotegerin concentrations and endothelial dysfunction in non-obese women with and without polycystic ovary syndrome. Arch Gynecol Obstet 2015;291:1075-80.
25
Gokce N, Keaney JF Jr, Hunter LM, Watkins MT, Menzoian JO, Vita JA. Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function: a prospective study. Circulation 2002;105:1567-72.
26
Pepene CE, Ilie IR, Marian I, Duncea I. Circulating osteoprotegerin and soluble receptor activator of nuclear factor kB ligand in polycystic ovary syndrome: relationships to insulin resistance and endothelial dysfunction. European Journal of Endocrinology 2011;164:61-8.
27
Escobar-Morreale HF, Botella-Carretero JI, Martínez-García MA, et al. Serum osteoprotegerin concentrations are decreased in women with the polycystic ovary syndrome.Eur J Endocrinol 2008;159:225-32.
28
Jono S, Ikari Y, Shioi A, et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 2002;106:1192-4.
29
Avignon A, Sultan A, Piot C, et al. Osteoprotegerin: a novel independent marker for silent myocardial ischemia in asymptomatic diabetic patients. Diabetes Care 2007;30:2934-9.
30
McGonigle JS, Giachelli CM, Scatena M. Osteoprotegerin and RANKL differentially regulate angiogenesis and endothelial cell function. Angiogenesis 2009;12:35-46.
31
Baud’huin M, Duplomb L, Teletchea S, et al.Osteoprotegerin: multiple partners for multiple functions. Cytokine and Growth Factor Reviews 2013;24:401-9.
32
Wright HL, McCarthy HS, Middleton J, Marshall MJ. RANK, RANKL and osteoprotegerin in bone biology and disease. Current Reviews in Musculoskeletal Medicine 2009;2:56-64.
33
Morony S, Tintut Y, Zhang et al Z. Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in Idlr(−/−) mice. Circulation 2008;117:411-20.
34
Holecki M, Zahorska-Markiewicz B, Janowska J, et al. The influence of weight loss on serum osteoprotegerin concentration in obese perimenopausal women. Obesity (Silver Spring) 2007;15:1925-9.
35
Gannage-Yared MH, Yaghi C, Habre B, et al. Osteoprotegerin in relation to body weight, lipid parameters insulin sensitivity, adipocytokines, and C-reactive protein in obese and non-obese young individuals: results from both cross-sectional and interventional study. Eur J Endocrinol 2008;158:353-9.
36
Victor RG, Haley RW, Willett DWL, et al. The Dallas Heart Study: A population-based probability sample for the multidisciplinary study of ethnic differences in cardiovascular health. J Am Cardiol 2004:1473-80.
37
Oh ES, Rhee EJ, Oh KW, Lee WY, Baek KH, Yoon KH. Circulating osteoprotegerin levels are associated with age, waist-to-hip ratio, serum-total cholesterol, and low-density lipoprotein cholesterol levels in healthy Korean women. Metabolism 2005;54: 49-54.
38
Gannage-Yared MH, Fares F, Semaan M, Khalife S, Jambart S. Circulation osteoprotegerin is correlated with lipid profile, insulin sensitivity adiponectin and sex steroids in an ageing male population. Clin Endocrinol 2006;64:652-8.
39
Browner WS, Lul LY, Cumming SR. Association of serum osteoprotegerin levels with diabetes,stroke, bone density, fractures, and mortality in elderly women. J Clinic Endocrinol Metab 2001;86:631-7.
40
Bernardi S, Fabris B, Thomas M, et al. Osteoprotegerin increases in metabolic syndrome and promotes adipose tissue proinflammatory changes. Mol Cell Endocrinol 2014;394:13-20.